PHBI – Pharmagreen Provides Updates On Its Business Developments Beyond Just Cannabis

CARSON CITY, NV, July 12, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Pharmagreen Biotech, Inc., (OTC-BB:PHBI), (“Pharmagreen” or the “Company”) is pleased to announce that, while focused on near term revenue from cannabis, the Company has commenced additional cultivation of other highly valued pharmaceutical plant species and functional therapeutic fungi species. Utilizing the Company's expertise in plant genetics and proprietary tissue culture technologies, Pharmagreen's transgenic program uses the newest technology available to research and create nutraceuticals, protein-based formulations, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.